NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of host-mimetic nanomedicine, has reaffirmed its commitment to combating the MPox virus following the World Health Organization’s decision to extend the Public Health Emergency of International Concern (PHEIC). The company’s focus is on NV-387, a broad-spectrum antiviral drug that has successfully completed Phase I trials, demonstrating a strong safety profile, and is now moving towards Phase II trials in Africa.

The significance of NV-387 lies in its unique mechanism of action, which mimics human cell features to prevent viral entry, potentially offering a solution to the limitations of current treatments like tecovirimat and brincidofovir. These existing options have been hampered by limited efficacy and adverse effects, making NV-387’s development a critical advancement in the fight against MPox and other viral infections.

NanoViricides, Inc. views the upcoming Phase II trials as a pivotal step not only in addressing the immediate public health crisis but also in tapping into lucrative markets, including government bioterrorism stockpiles. The company’s progress with NV-387 represents a beacon of hope in the global effort to mitigate the impact of MPox and underscores the importance of innovative antiviral therapies in public health preparedness.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NanoViricides, Inc. Advances MPox Treatment Amid WHO’s Extended Global Health Emergency.